Long Term Effect of Autoadjusting Positive Airway Pressure on C-Reactive Protein and Interleukin-6 in Men With Obstructive Sleep Apnoea Syndrome;Efecto a largo plazo de la presión positiva automática en la vía aérea sobre la proteína C reactiva y la interleucina-6 en varones con síndrome de apnea obstructiva del sueño

Archivos de Bronconeumologia

Volumn 45, Issue 12, 2009, Pages 577-584

  Drummond, Marta ^a   Winck, João ^a   Guimarães, João ^a   Santos, Ana C ^a   Almeida, João ^a   Marques, João ^a  

^a São João University Hospital   (Portugal)

Author keywords

High sensitivity C reactive protein; Interleukin 6; Obstructive sleep apnoea

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SHORT COURSE THERAPY; SLEEP APNEA SYNDROME; THERAPY EFFECT;

EID: 70449096325     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(09)73447-0     Document Type: Article

References (57)

1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., and Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328 (1993) 1230-1235
2. Shahar E., Whitney C.W., Redline S., Lee E.T., Newman A.B., Nieto F.J., et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health. Am J Respir Crit Care Med 163 (2001) 19-25
3. Leung R.S., and Bradley T.D. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 164 (2001) 2147-2165
4. Newman A.B., Nieto F.J., Guidry U., Lind B.K., Redline S., Pickering T.J., et al. Relation of sleep-disordered breathing to cardiovascular disease risk factors: The Sleep Heart Health Study. Am J Epidemiol 154 (2001) 50-59
5. Somers V.K., Dyken M.E., Clary M.P., and Abboud F.M. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96 (1995) 1897-1904
6. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Kales A., Tyson K., and Chrousos G.P. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 82 (1997) 1313-1316
7. Liu H., Liu J., Xiong S., Shen G., Zhang Z., and Xu Y. The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome. J Tongji Med Univ 20 (2000) 200-202
8. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Hopper K., Lotsikas A., Lin H., et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 85 (2000) 1151-1158
9. Yokoe T., Minoguchi K., Matsuo H., Oda N., Minoguchi H., Yoshino G., et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107 (2003) 1129-1134
10. Shamsuzzaman A.S.M., Winnicki M., Lanfranchi P., Wolk R., Kara T., Accurso V., et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105 (2002) 2462-2464
11. Kokturk O., Ciftci T.U., Mollarecep E., and Ciftci B. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 46 (2005) 801-809
12. Barceló A., Barbé F., Llompart E., Mayoralas L.R., Ladaria A., Bosch M., et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Respir Crit Care Med 117 (2004) 118-121
13. Guilleminault C., Kirisoglu C., and Ohayon M.M. C-reactive protein and sleep-disordered breathing. Sleep 27 (2004) 1507-1511
14. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
15. Harris T.B., Ferruci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger Jr. W.H., et al. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
16. Pasulka P., Bristian B.R., and Blackburn G.L. Obesity and erythrocyte sedimentation rates. Ann Intern Med 103 (1985) 304
17. Roytblat L., Rachinsky M., Fisher A., Greemberg L., Shapira Y., Douvdevani A., et al. Raised interleukin-6 levels in obese patients. Obes Res 8 (2000) 673-675
18. Meier-Ewert H.K., Ridker P.M., Rifai N., Price N., Dinges D.F., and Mullington J.M. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47 (2001) 426-430
19. Lindhal B., Toss H., Siegbahn A., Venge P., and Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary heart disease. FRISC Study Group. N Engl J Med 343 (2000) 1139-1147
20. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
21. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
22. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 321 (2000) 199-204
23. Jialal I., Devaraj S., and Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 44 (2004) 6-11
24. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
25. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
26. Han K.H., Hong K.H., Park J.H., Ko J., Kang D.H., Choi K.J., et al. C-reactive protein promotes monocyte chemoattractant protein-I-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 109 (2004) 2566-2571
27. Fichlscherer S., Breuer S., Schachinger V., Dimmeler S., and Zeiher A.M. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 25 (2004) 1412-1418
28. Hartmann G., Tschop M., Fischer R., Bidlingmaier C., Riepl R., Tschöp K., et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 12 (2000) 246-252
29. Tauman R., Ivanenko A., O'Brien L.M., and Gozal D. Plasma C-reactive protein levels among children with sleep-disordered breathing. Pediatrics 113 (2004) e564-e569
30. Sullivan C.E., Issa F.G., Berthon-Jones M., and Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1 (1981) 862-865
31. Giles T., Lasserson T., Smith B.J., White J., Wright J., and Cates C.J. Continuous positive airways pressure for obstructive leep apnoea in adults. Cochrane Database Syst Rev 1 (2006) CD001106
32. Peker Y., Hedner J., Norum J., Kraiczi H., and Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7 year follow-up. Am J Respir Crit Care Med 166 (2002) 159-165
33. Milleron O., Pilliere R., Foucher A., De Roquefeuil F., Aegerter P., Jondeau G., et al. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 25 (2004) 728-734
34. Arias M.A., García-Río F., Alonso-Fernández A., Hernanz A., Hidalgo R., Martínez-Mateo V., et al. CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea. Eur Respir J 32 (2008) 1009-1015
35. Nussbaumer Y., Block K.E., Genser T., and Thurneer R. Equivalence of autoadjusted and constant continuous positive airway pressure in home treatment of sleep apnea. Chest 129 (2006) 638-643
36. Massie C.A., McArdle N., Hart R.W., Schmidt-Nowara W.W., Lankford A., Hudgel D.W., et al. Comparison between automatic and fixed positive airway pressure therapy in the home. Am J Respir Crit Care Med 167 (2003) 20-23
37. Stradling J.R. Reducing the cost of treating obstructive sleep apnoea: good news for the patients. Am J Respir Crit Care Med. 170 (2004) 1143-1144
38. Patruno V., Aiolfi S., Costantino G., Murgia R., Selmi C., Malliani A., et al. Fixed and autoadjusting continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep apnea. Chest 131 (2007) 1393-1399
39. Ramos E., Lopes C., and Barros H. Investigating the effect of nonparticipation using a population-based case-control study on myocardial infarction. Ann Epidemiol 14 (2004) 437-441
40. Folstein M., Folstein S., and Mchush P. "Mini mental state". A pratical method for grading the cognitive state of patients for the clinician. J Psych Res. 12 (1975) 189-198
41. García-Díaz E., Quintana-Gallego E., Ruiz A., Carmona-Bernal C., Sánchez-Armengol A., Botebol-Benhamou G., et al. Respiratory poligraphy with actigraphy in the diagnosis of sleep apnea-hypopnea syndrome. Chest 131 (2007) 725-732
42. The report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults:recommendations for syndrome definition and measurement techniques in clinical research. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force. Sleep 22 (1999) 667-689
43. Bray G.A. Pathophysiology of obesity. Am J Clin Nutr 55 (1992) 4883-4943
44. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. New European guidelines on treatment of hypertension. J Hypertens 25 (2007) 1751-1762
45. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 31 (2008) S55-S60
46. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., American Heart Association; National Heart, Lung, and and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
47. Ridker P.M. High-sensitivity C-reactive protein:potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
48. Albert M.A., Danielson E., Rifai N., Ridker P.M., and PRINCE Investigators. Effect of statin therapy on C-reactive protein levels:the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
49. Pasceri V., Cheng J.S., Willerson J.T., and Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
50. Nakajima T., Schulte S., Warrington K.J., Kopecky S.L., Frye R.L., Goronzy J.J., et al. T-cell mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105 (2002) 570-575
51. Ahashiba T., Akahoshi T., Kawahara S., Majima T., and Horie T. Effects of long-term nasal continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea syndrome. Intern Med 44 (2005) 899-900
52. Ryan S., Nolan G., Hannigan E., Cunningham S., Taylor C., and McNicholas W.T. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 62 (2007) 509-514
53. Biffl W.L., Moore E.E., Moore F.A., and Peterson V.M. Interleukin-6 in the injured patient. Ann Surg 224 (1996) 647-664
54. Vgontzas N.A., Zoumakis E., Lin H.-M., Bixler E.O., Trakada G., and Chrousos G.P. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-α antagonist. J Clin Endocrinol Metab 89 (2004) 4409-4413
55. Vgontzas A.N., Zoumakis E., Bixler E.O., Lin H.M., Collins B., Basta M., et al. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest 38 (2008) 585-595
56. Plenge J.K., Hernández T.L., Weil K.M., Poirier P., Grunwald G.K., Marcovina S.M., et al. Sinvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
57. Sharma S.K., Mishra H.K., Sharma H., Goel A., Sreenivas V., Glati V., et al. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep disordered breathing in Delhi. Sleep Med 9 (2008) 149-156